Quote | Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX)
Last: | $1.92 |
---|---|
Change Percent: | 1.53% |
Open: | $1.93 |
Close: | $1.92 |
High: | $2 |
Low: | $1.9 |
Volume: | 621,215 |
Last Trade Date Time: | 07/24/2024 03:00:00 am |
News | Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX)
2024-07-10 15:14:20 ET More on Amylyx, Eiger, etc. Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition Amylyx Pharmaceuticals, Inc. (...
2024-07-10 14:23:09 ET Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call July 10, 2024 08:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Joshua Cohen - C...
Message Board Posts | Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX)
Subject | By | Source | When |
---|---|---|---|
Another viewpoint on the ALS drug | conix | investorshub | 10/16/2022 5:13:45 PM |
Ya Max, I see it kicking up it | MiamiGent | investorshub | 10/11/2022 1:24:33 AM |
Notice the cup and handle formation- super bullish | Max77 | investorshub | 10/10/2022 6:53:01 PM |
. $AMLX Amylyx Pharmaceuticals Receives FDA Approval Of Relyvrio | MiamiGent | investorshub | 09/30/2022 3:11:16 AM |
$AMLX The Motley Fool | MiamiGent | investorshub | 09/27/2022 7:41:18 PM |
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...